Analysis of publicly available RNA-seq and copy number data reflected a similar expression trend with higher CYB561 mRNA levels in PRAD versus normal tissue samples (Fig 1B), and increasing CYB561 amplification frequency as PCa progresses from PRAD to CRPC and eventually NEPC (Fig 1C). The gene discussed is CYB561; the disease is prostate adenocarcinoma.